EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Silke Gillessen et al.|European Urology|2019Cited by 191
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic TherapiesShiven B. Patel, Neeraj Agarwal, David D. Stenehjem et al.|Clinical Genitourinary Cancer|2015Cited by 15
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.Zachary A. Yochum, Toni K. Choueiri, Renée Maria Saliby et al.|Journal of Clinical Oncology|2025Cited by 0